Document is current
Any future updates will be listed below
-
Authors
Yisimayi, Ayijiang https://orcid.org/0000-0003-0648-1864
Song, Weiliang
Wang, Jing https://orcid.org/0000-0002-9084-9985
Jian, Fanchong https://orcid.org/0000-0001-8703-3507
Yu, Yuanling
Chen, Xiaosu
Xu, Yanli
Yang, Sijie https://orcid.org/0009-0001-9834-4340
Niu, Xiao
Xiao, Tianhe
Wang, Jing
Zhao, Lijuan
Sun, Haiyan
An, Ran
Zhang, Na
Wang, Yao
Wang, Peng
Yu, Lingling
Lv, Zhe
Gu, Qingqing https://orcid.org/0000-0001-5805-6419
Shao, Fei
Jin, Ronghua https://orcid.org/0000-0001-8496-172X
Shen, Zhongyang https://orcid.org/0000-0003-0045-4355
Xie, Xiaoliang Sunney https://orcid.org/0000-0001-9281-5239
Wang, Youchun https://orcid.org/0000-0001-9769-5141
Cao, Yunlong https://orcid.org/0000-0001-5918-1078
- License Information
-
More Information
Article History
Received: 2 May 2023
Accepted: 17 October 2023
First Online: 22 November 2023
Competing interests
: X.S.X. and Y.C. are inventors on the provisional patent applications of BD series antibodies, which include BD55-5514 (SA55) and monoclonal antibodies from Omicron infection convalescents. X.S.X. and Y.C. are founders of Singlomics Biopharmaceuticals. The other authors declare no competing interests.
